Dr. James Mccallum Noble's lab is focused on understanding the links between oral health, specifically periodontal infections, and Alzheimer's Disease. They are investigating how periodontitis may contribute to cognitive impairment and dementia in older adults. By studying a diverse group of elderly participants over time, they aim to uncover potential mechanisms connecting these two health issues and provide insights for prevention and early intervention strategies.

Dr. Hemali Phatnani's lab at Columbia University Health Sciences focuses on understanding the mechanisms behind neurodegenerative diseases like Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD). The lab investigates how protein aggregation—especially that of TDP-43—can lead to damage in nerve cells and contributes to these diseases. They aim to uncover the physical and molecular changes that predispose certain cells to disease and develop new treatment strategies that could improve patient outcomes.

Dr. Franck Polleux's lab at Columbia University focuses on understanding the development and evolution of brain circuits, particularly how unique human features emerge at the molecular level. The lab investigates how specific proteins and genes influence the structure and function of neurons and synapses, which could reveal insights into the biology of human cognitive capabilities and disorders. Through their research, they aim to uncover the cellular mechanisms involved in brain development and their implications for neurodevelopmental and neurodegenerative diseases.

Dr. Joriene De Nooij's lab at Columbia University is focused on understanding the development and function of proprioceptors, which are specialized sensory neurons that help our body sense position and movement. They study how these neurons develop different identities based on the types of sensory information they receive. By exploring the genetic and molecular dynamics involved in this process, their research aims to improve treatment strategies for spinal cord injuries and enhance our understanding of movement control in the nervous system.

Dr. Christiane Reitz's lab focuses on understanding the genetic factors contributing to neuropsychiatric symptoms in Alzheimer's disease, particularly in diverse populations such as Hispanic and African-American individuals. They aim to create a large, harmonized dataset that includes genetic, neuroanatomical, and clinical data to better understand how ancestry influences these symptoms and to ultimately inform better treatment options. This research is crucial as it endeavors to address historical gaps in Alzheimer's research and improve outcomes for affected populations.

Dr. Steven Siegelbaum's lab at Columbia University focuses on understanding how the brain processes social memories, specifically through the hippocampus and its CA2 region. The research explores how the brain distinguishes between rewarding and threatening social interactions, which is crucial for social functioning. By using animal models, the lab aims to uncover the neural circuits involved in memory and social behavior, and how alterations in these circuits may be linked to conditions like anxiety and schizophrenia.

Dr. Yaakov Stern's lab at Columbia University focuses on understanding the relationship between cognitive aging and Alzheimer’s disease (AD). The team uses advanced imaging techniques to explore how neural networks associated with memory and other cognitive abilities change with age and how modern family and work life impacts the risk of developing Alzheimer's disease. By studying diverse populations, they aim to identify key factors that could help prevent cognitive decline in older adults.

Dr. Catarina M. Quinzii's lab at Columbia University focuses on understanding the molecular mechanisms behind frontotemporal dementia (FTD) caused by abnormal Tau protein. The lab investigates how a process called SUMOylation influences Tau behavior and its impact on brain function, specifically regarding mitochondria and synapses. By using animal models and cell lines derived from patients, the team aims to identify potential therapeutic strategies to improve cognitive functions in FTD.

Dr. Giuseppe Tosto's lab at Columbia University focuses on understanding Alzheimer's disease, particularly within Hispanic/Latino populations. Acknowledging that these groups have a higher prevalence of Alzheimer's, the lab aims to enhance genetic research by sequencing the genomes of 6,000 individuals from diverse Hispanic backgrounds, especially those with significant Native American ancestry. This work will help in uncovering rare genetic variants associated with the disease and improving our understanding of Alzheimer's in underrepresented populations.

Dr. Ai Yamamoto's lab at Columbia University focuses on understanding and addressing neurodegenerative diseases such as Parkinson's and Alzheimer's. The research primarily investigates the role of autophagy, a key cellular process that cleans out damaged components in neurons, and how its dysfunction contributes to these diseases. By examining specific cellular pathways, including calcium signaling and the role of certain proteins, the lab aims to identify potential therapeutic targets to treat these debilitating conditions.

Dr. Soojin Park's lab at Columbia University Health Sciences focuses on improving the management of patients suffering from acute hydrocephalus and delayed cerebral ischemia, particularly after brain injuries like subarachnoid hemorrhages. The lab leverages machine learning and artificial intelligence to develop predictive models that help identify complications early, aiming to reduce hospital stays and improve patient outcomes. Research utilizes data from patient monitoring to enhance decision-making processes in critical care settings.

Dr. C. Daniel Salzman's lab at Columbia University focuses on understanding how the brain makes decisions and processes social information. They explore neural mechanisms involved in decision-making, especially in novel situations and when responding to social cues, using techniques like electrophysiology and behavioral assays. Research from this lab aims to shed light on the complexities of motivated behavior and emotional regulation, particularly in the context of psychiatric disorders.

Scott A Small's lab at Columbia University Health Sciences focuses on understanding the role of the SORL1 gene in Alzheimer's disease. They investigate how different variants of this gene contribute to the disease's development and progression, particularly through its interaction with the retromer trafficking complex. The lab aims to decipher the mechanisms behind these variants to inform potential therapies for patients with Alzheimer's, especially those with specific genetic mutations.

Dr. Vilas Menon's lab at Columbia University focuses on understanding the complex interactions between different cell types involved in Alzheimer's Disease (AD). By using induced pluripotent stem cells (iPSCs) from donors with varying AD pathology, the lab aims to explore how these cells communicate and influence each other in the progression of cognitive decline. This research is critical for identifying potential clinical targets for Alzheimer's intervention.

Dr. Olajide Williams leads a research lab at Columbia University focused on improving stroke outcomes by addressing social determinants of health (SDOH). Their main project, the SHIFT Trial, investigates how a community-based approach led by health workers can help stroke patients recover better by providing support that tackles the challenges posed by their social and economic conditions. The lab aims to demonstrate that improving these factors can reduce disability and enhance quality of life after a stroke, making healthcare more equitable for vulnerable populations.